{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:25:18Z","timestamp":1783952718029,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Financial support for this study"],"award-info":[{"award-number":["Financial support for this study"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Financial support for this study"],"award-info":[{"award-number":["Financial support for this study"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD19-directed chimeric antigen receptor T cells (CAR-T) have emerged as a highly efficacious treatment for patients with relapsed\/refractory (r\/r) B cell lymphoma (BCL). The value of CAR-T for these patients is indisputable, but one-off production costs are high, and little is known about the ancillary resource consumption associated with CAR-T treatment. Here, we compared the resource use and costs of CAR-T treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for patients with r\/r BCL. Standard operating procedures were used to develop a process model in ClipMed<jats:sup>PPM<\/jats:sup>, which comprises all activities and processes to sustain or generate treatment components that together constitute a treatment path. The software allows a graphic representation and the use of standardized linguistic elements for comparison of different treatment paths. Detailed processes involved in CAR-T treatments (<jats:italic>n<\/jats:italic>\u2009=\u20091041 processes) and in ASCT (<jats:italic>n<\/jats:italic>\u2009=\u20091535) were analyzed for time consumption of treatment phases and personnel. Process costs were calculated using financial controlling data. CAR-T treatment required\u2009~\u200930% less staff time than ASCT (primarily nursing staff) due to fewer chemotherapy cycles, less outpatient visits, and shorter hospital stays. For CAR-T, production costs were\u2009~\u20098\u2009\u00d7\u2009higher, but overall treatment time was shorter compared with ASCT (30 vs 48\u00a0days), and direct labor and overhead costs were 40% and 10% lower, respectively. Excluding high product costs, CAR-T uses fewer hospital resources than ASCT for r\/r BCL. Fewer hospital days for CAR-T compared to ASCT treatment and the conservation of hospital resources are beneficial to patients and the healthcare system.<\/jats:p>","DOI":"10.1007\/s00277-022-04881-0","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T04:02:38Z","timestamp":1656302558000},"page":"1755-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Alexander","family":"Ring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rk","family":"Volbracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Sch\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Greiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M. S.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"issue":"5","key":"4881_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"1","key":"4881_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"1","key":"4881_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"10254","key":"4881_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet Lond Engl 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet Lond Engl"},{"issue":"14","key":"4881_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"8","key":"4881_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC et al (2021) Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"27","key":"4881_CR7","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ et al (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol Off J Am Soc Clin Oncol 38(27):3119\u20133128. https:\/\/doi.org\/10.1200\/JCO.19.02104","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"4881_CR8","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G et al (2021) Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med 10(10):3214\u20133223. https:\/\/doi.org\/10.1002\/cam4.3881","journal-title":"Cancer Med"},{"issue":"7","key":"4881_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR et al (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 56(7):1651\u20131664. https:\/\/doi.org\/10.1038\/s41409-021-01227-8","journal-title":"Bone Marrow Transplant"},{"key":"4881_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","author":"FL Locke","year":"2021","unstructured":"Locke FL et al (2021) Axicabtagene ciloleucel as second-line therapy for large B-cell Lymphoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"issue":"6","key":"4881_CR11","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","volume":"38","author":"M Moradi-Lakeh","year":"2021","unstructured":"Moradi-Lakeh M, Yaghoubi M, Seitz P, Javanbakht M, Brock E (2021) Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-Cell lymphoma (DLBCL) in Switzerland. Adv Ther 38(6):3427\u20133443. https:\/\/doi.org\/10.1007\/s12325-021-01767-x","journal-title":"Adv Ther"},{"issue":"9","key":"4881_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","volume":"55","author":"S Fiorenza","year":"2020","unstructured":"Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA (2020) Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant 55(9):1706\u20131715. https:\/\/doi.org\/10.1038\/s41409-020-0956-8","journal-title":"Bone Marrow Transplant"},{"issue":"32","key":"4881_CR13","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK et al (2018) Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 36(32):3192\u20133202. https:\/\/doi.org\/10.1200\/JCO.2018.79.0642","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"4881_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA et al (2018) Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ 21(12):1238\u20131245. https:\/\/doi.org\/10.1080\/13696998.2018.1529674","journal-title":"J Med Econ"},{"issue":"7","key":"4881_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD (2019) Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst 111(7):719\u2013726. https:\/\/doi.org\/10.1093\/jnci\/djy193","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4881_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD et al (2019) Long-term survival and cost-effectiveness associated with Axicabtagene ciloleucel vs Chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open 2(2):e190035. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0035","journal-title":"JAMA Netw Open"},{"issue":"24","key":"4881_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD (2019) Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 37(24):2105\u20132119. https:\/\/doi.org\/10.1200\/JCO.18.02079","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"27","key":"4881_CR18","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol 28(27):4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4881_CR19","unstructured":"Greiling M, Osygus M, \u201cProzessmanagement. Der Pfad- und Prozesskostenmanager f\u00fcr die Patientenversorgung.,\u201d Mediengruppe Oberfranken, 2014."},{"key":"4881_CR20","unstructured":"Greiling M, \u201cProzessmanagement - Der Prozesskostenmanager f\u00fcr die Patientenversorgung,\u201d Baumann Fachverlage, 2008."},{"key":"4881_CR21","unstructured":"Greiling M, Thomas F, Muszynski T, \u201cSoftwaregest\u00fctzte Erstellung Klinischer - Pfade mit integrierter Prozesskostenrechnung.,\u201d Baumann Fachverlage, 2005."},{"key":"4881_CR22","doi-asserted-by":"crossref","unstructured":"Greiling M (Hrsg.), \u201cPfade durch das klinische Proze\u00dfmanagement - Methodik und aktuelle Diskussionen in deutschen Krankenh\u00e4usern.,\u201d Kohlhammer, 2003.","DOI":"10.17433\/978-3-17-026539-4"},{"key":"4881_CR23","unstructured":"Greiling, M., \u201cWorkflow-Management Exzellenz-Modell - Eine Erfolgsstrategie f\u00fcr mehr Zeit durch weniger Verschwendung.,\u201d 2019th ed., vol. Band 2; Wege zur Effektivit\u00e4t, Mediengruppe Oberfranken."},{"issue":"2","key":"4881_CR24","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine R et al (2021) Health economic aspects of chimeric antigen receptor t-cell therapies for hematological cancers: present and future. HemaSphere 5(2):e524. https:\/\/doi.org\/10.1097\/HS9.0000000000000524","journal-title":"HemaSphere"},{"key":"4881_CR25","doi-asserted-by":"publisher","unstructured":"C. Quinn, C. Young, J. Thomas, M. Trusheim, and MIT NEWDIGS FoCUS Writing Group, \u201cEstimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system,\u201d Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res., vol. 22, no. 6, pp. 621\u2013626, Jun. 2019 https:\/\/doi.org\/10.1016\/j.jval.2019.03.014","DOI":"10.1016\/j.jval.2019.03.014"},{"issue":"Supplement 1","key":"4881_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2021-148039","volume":"138","author":"FL Locke","year":"2021","unstructured":"Locke FL (2021) Primary Analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) Versus standard-of-care therapy in patients with relapsed\/refractory large B-cell lymphoma. Blood 138(Supplement 1):2","journal-title":"Blood"},{"key":"4881_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","author":"MR Bishop","year":"2021","unstructured":"Bishop MR et al (2021) Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2116596","journal-title":"N Engl J Med"},{"key":"4881_CR28","unstructured":"Kamdar M, et al (2021) Lisocabtagene maraleucel (liso-cel), a cd19-directed chimeric antigen receptor (CAR) T cell therapy, Versus Standard of Care (SOC) with Salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) As second-line (2L) treatment in patients (Pts) with Relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. ASH Annu. Meet"},{"issue":"Supplement 1","key":"4881_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-134449","volume":"136","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS et al (2020) Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) With high-risk large b cell lymphoma (LBCL). Blood 136(Supplement 1):49","journal-title":"Blood"},{"issue":"Supplement 1","key":"4881_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2021-148009","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS et al (2021) Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) As first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood 138(Supplement 1):739","journal-title":"Blood"},{"issue":"1","key":"4881_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13696998.2021.1894158","volume":"24","author":"CL Simons","year":"2021","unstructured":"Simons CL et al (2021) Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States. J Med Econ 24(1):421\u2013431. https:\/\/doi.org\/10.1080\/13696998.2021.1894158","journal-title":"J Med Econ"},{"issue":"4","key":"4881_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1377\/hlthaff.23.4.202","volume":"23","author":"AE Rogers","year":"2004","unstructured":"Rogers AE, Hwang W-T, Scott LD, Aiken LH, Dinges DF (2004) The working hours of hospital staff nurses and patient safety. Health Aff Proj Hope 23(4):202\u2013212. https:\/\/doi.org\/10.1377\/hlthaff.23.4.202","journal-title":"Health Aff Proj Hope"},{"issue":"16","key":"4881_CR33","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1001\/jama.288.16.1987","volume":"288","author":"LH Aiken","year":"2002","unstructured":"Aiken LH, Clarke SP, Sloane DM, Sochalski J, Silber JH (2002) Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction. JAMA 288(16):1987\u20131993. https:\/\/doi.org\/10.1001\/jama.288.16.1987","journal-title":"JAMA"},{"issue":"2","key":"4881_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1634\/theoncologist.7-2-120","volume":"7","author":"A Bottomley","year":"2002","unstructured":"Bottomley A (2002) The cancer patient and quality of life. Oncologist 7(2):120\u2013125. https:\/\/doi.org\/10.1634\/theoncologist.7-2-120","journal-title":"Oncologist"},{"issue":"7","key":"4881_CR35","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/pon.5054","volume":"28","author":"A Shrestha","year":"2019","unstructured":"Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L (2019) Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology 28(7):1367\u20131380. https:\/\/doi.org\/10.1002\/pon.5054","journal-title":"Psychooncology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T19:38:04Z","timestamp":1700768284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4881"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04881-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary data are available on request from bgrob@hemap.ch.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"ClipMed PPM Version 4.4.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AMSM received honoraria from Celgene\/BMS, Novartis, Kite\/Gilead, and Janssen for advisory boards and lecture activities. MG is the scientific director of software-based academic training with a university certificate for Certified Workflow Manager in Health Care with the ClipMed PPM application and was remunerated by Celgene\/BMS for this analysis. BG is a partner of HEMAP AG (Health Economics Market Access Pricing) and was remunerated by Celgene\/BMS for this analysis.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}